We're transitioning our Q4 and full year 2023 revenue guidance to be reported on an adjusted revenue basis. Our outlook for 4Q adjusted revenue is 188,000,000 dollars to $194,000,000 which represents mid single digit year over year adjusted revenue growth as well as growth acceleration from the 3rd quarter. We expect adjusted and GAAP revenue to be identical in the 4th quarter because the 3rd quarter adjustment to revenue in relation to the Pharma Manufacturer Solutions restructuring related to Vitacare was solely one time and non recurring. Previously, our full year GAAP revenue guidance range was $750,000,000 to $760,000,000 After adding back the $10,000,000 client contract termination payment to GAAP revenue, we continue to expect we will be within that range with adjusted revenue between $752,000,000 $758,000,000 From a margin perspective, during the last couple of quarters, we've delivered adjusted EBITDA margins in the high 20s and we're expecting to be in the mid to high 20% range again in the 4th quarter, which implies high 20% adjusted EBITDA margin for the full year above our prior guidance of mid to high 20%. Moving on to 4th quarter guidance by offering, We expect prescription transactions revenue of approximately $133,000,000 to $136,000,000 We expect Pharma Manufacturer Solutions revenue of approximately $27,000,000 to $30,000,000 This guidance range reflects our continued rationalizing of this offering, including deprioritizing of VidaCare services.